SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (996)6/21/1999 9:47:00 AM
From: BulbaMan  Respond to of 1073
 
Rick: Thanks for your prompt response. I think there is a pulse. IMHO, at under $2 a share, MAGN simply has a good risk/reward ratio -- the price doesn't reflect any possible good news (e.g., from the FDA or a squalamine partnership). Here's a link to their latest squalamine press release: biz.yahoo.com



To: scaram(o)uche who wrote (996)6/21/1999 3:17:00 PM
From: LLCF  Respond to of 1073
 
Janssen Pharm announces the withdrawal of prescription antihistamine HISMANAL from the market.
Adverse reaction data finally did it in.

Good for SEPR... eh eh.

DAK



To: scaram(o)uche who wrote (996)6/25/1999 2:08:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1073
 
current ask 5 1/8, addition made to "neuro" (eom)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News